Intra-Cellular Therapies Inc (STU:23I)
€ 81.5 2 (2.52%) Market Cap: 8.63 Bil Enterprise Value: 7.68 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 60/100

Intra-Cellular Therapies Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 09:20PM GMT
Release Date Price: €58.2 (+1.22%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

All right, everybody. We're going to get going with our next company presenter here at the BofA Annual Healthcare Conference. My name is Jason Gerberry, I'm one of the biopharma analysts. Pleased to be introducing Intra-Cellular Therapies, Intra-Cellular Therapeutics, and Mark Neumann, Chief Commercial Officer. So Mark, first, thanks for joining us. And I think you have a brief prepared remarks, and then we'll jump into Q&A.

Mark Neumann
Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer

Yes. Thank you. Thanks for the invitation, and we're really pleased to be here to be able to share the progress that we're making at ITCI. But before we start, I'll be making some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results may differ, so I refer you to our website and to our SEC filings for updates on the company.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot